Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong Qilu Stem Cells Engineering Co., Ltd.
• Treatments: Adalimumab; Azathioprine; Prednisone

Criteria

Inclusion Criteria:

• 1. Western medicine diagnosis is consistent with patients with refractory ulcerative colitis.

• 2. 18 Years to 65 Years，male or female.

• 3. Those who voluntarily participate in this clinical study and have signed an informed consent.

Exclusion Criteria:

• 1. Patients with non-refractory UC.

• 2. Those who are pregnant or breastfeeding, or have a childbirth plan in the near future.

• 3. People with severe allergies or allergies to known ingredients in basic treatments.

• 4. Patients with severe primary diseases such as severe cardiovascular and cerebrovascular diseases, liver and kidney, and hematopoietic system.

• 5. There are serious complications, such as local stenosis, intestinal obstruction, intestinal perforation, multiple intestinal polyps, toxic megacolon, rectal cancer, etc..

• 6. Patients with mental disorders and intellectual disabilities.

• 7. Patients who have participated in clinical studies of other drugs in the past 3 months.

• 8. Those who are seriously ill and need emergency treatment.

• 9. Patients who are still undergoing other treatment options for ulcerative colitis.

• 10. Researchers believe that it is not suitable for entry.